|
|
| (83 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32362782|t=2020. Aktuelle Informationen zu COVID-19 auf einer Plattform ? zeitschriftenübergreifend |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32330209|t=ä. A precision medicine approach to managing 2019 novel coronavirus pneumonia |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32278960|t=2020. COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us |pdf=|usr=}}
| + | |
| − | {{tp|p=32345483|t=ä. CCOVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause |pdf=|usr=}}
| + | |
| − | {{tp|p=32334862|t=ä. COVID-19�: caract�ristiques cliniques, biologiques et radiologiques chez l?adulte, la femme enceinte et l?enfant Une mise au point au c?ur de la pand�mie |pdf=|usr=}}
| + | |
| − | {{tp|p=32336927|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, History, Basic and Clinical Aspects |pdf=|usr=}}
| + | |
| | | | |
| − |
| |
| − |
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32327870|t=ä. Recomendaciones sobre el tratamiento antitromb�tico durante la pandemia COVID-19 Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espa�ola de Cardiolog�a |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 21: |
Zeile 13: |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=C7187661|t=ä. Group Testing for SARS-CoV-2: Forward to the Past?|pdf=|usr=}}
| |
| − | {{tp|p=32329979|t=2020. COVID-19 rapid antibody cassette point of care tests: practical considerations |pdf=|usr=}}
| |
| − | {{ttp|p=32358057|t=2020. Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection |pdf=|usr=}}
| |
| − | {{ttp|p=32373393|t=ä. Rapid and Sensitive Detection of COVID-19 Using CRISPR/Cas12a-based Detection with Naked Eye Readout, CRISPR/Cas12a-NER |pdf=|usr=}}
| |
| − | {{tp|p=32270436|t=ä. Detection of serum IgM and IgG for COVID-19 diagnosis |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32321099|t=ä. COVID-19 - Computed tomography findings in two patients in Petr�polis, Rio de Janeiro, Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32267461|t=ä. Chest radiography and computed tomography findings from a Brazilian patient with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32215898|t=2020. CT-Morphologie von COVID-19: Fallbeispiel und Literaturubersicht |pdf=|usr=}}
| |
| − | {{tp|p=32193883|t=2020. CT appearance of severe, laboratory-proven coronavirus disease 2019 (COVID-19) in a Caucasian patient in Berlin, Germany |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32269081|t=2020. Phylogenetic network analysis of SARS-CoV-2 genomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32009228|t=2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32165541|t=2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells |pdf=|usr=}}
| |
| − | {{tp|p=32364961|t=2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − | {{ttp|p=32291557|t=ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32304647|t=2020. SARS-CoV-2 shedding and infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32304646|t=ä. SARS-CoV-2 shedding and infectivity ? Authors reply |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 62: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32292530|t=2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan|pdf=|usr=}}
| + | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| | | | |
| − | ----
| + | |
| | + | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32326988|t=ä. Lactose Dehydrogenase in Patients with Severe COVID-19: A Meta-Analysis of Retrospective Study }}
| |
| − | {{tp|p=32339247|t=ä. Does apolipoprotein E genotype predict COVID-19 severity?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| − | {{tp|p=32303993|t=ä. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32342879|t=ä. COVID-19 and radiation induced pneumonitis: overlapping clinical features of different diseases |pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| Zeile 86: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32222804|t=ä. Arthralgia as an initial presentation of COVID-19: observation |pdf=|usr=}}
| |
| | | | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32192233|t=2020. Co-infection with SARS-CoV-2 and Human Metapneumovirus |pdf=|usr=}}
| |
| − | {{tp|p=32170625|t=ä. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients |pdf=|usr=}}
| |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32356640|t=2020. SARS-CoV-2 pneumonia and pulmonary embolism in a 66-year-old female |pdf=|usr=}}
| + | |
| − | {{tp|p=32329980|t=2020. SARS-CoV-2 infection masquerading as a possible pulmonary embolism |pdf=|usr=}}
| + | |
| − | {{tp|p=32351657|t=ä. Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32294340|t=ä. Immune Thrombocytopenic Purpura in a Patient with Covid-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32372844|t=ä. COVID-19 y tratamiento guiado con tests de diagn�stico bioqu�micos y moleculares para reducir el da�o cardiaco y la cardiotoxicidad |pdf=|usr=}}
| + | |
| − | {{tp|p=32355394|t=ä. COVID-19 y shock cardiog�nico: diferentes formas de presentaci�n cardiovascular con alta mortalidad |pdf=|usr=}}
| + | |
| − | {{tp|p=32345547|t=ä. Fulminant myocarditis due to COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32267110|t=2020. COVID-19 et maladies cardiovasculaires |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32329044|t=2020. Complicaciones neurologicas por coronavirus y COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32359804|t=ä. Covid-19 and Guillain-Barr� syndrome: More than a coincidence!|pdf=|usr=}}
| + | |
| − | {{tp|p=32334841|t=ä. COVID-19 may induce Guillain-Barr� syndrome |pdf=|usr=}}
| + | |
| − | {{tp|p=32246403|t=ä. The brain, another potential target organ, needs early protection from SARS-CoV-2 neuroinvasion |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | + | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32328338|t=2020. Anal swab findings in an infant with COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32356641|t=2020. Addressing multiple gastroenterological aspects of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32250094|t=2020. Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32343593|t=2020. COVID-19, coronavirus, SARS-CoV-2 and the small bowel |pdf=|usr=}}
| |
| − | {{tp|p=32376072|t=ä. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Kidney, urology]]''' | | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32362571|t=2020. SARS-CoV-2 and the testis: similarity with other viruses and routes of infection |pdf=|usr=}}
| + | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=C7129713|t=ä. Coronavirus: la emergencia geri�trica de 2020 Documento conjunto de la Secci�n de Cardiolog�a Geri�trica de la Sociedad Espa�ola de Cardiolog�a y la Sociedad Espa�ola de Geriatr�a y Gerontolog�a |pdf=|usr=}}
| |
| − | {{tp|p=C7151242|t=ä. Controversy regarding ACE inhibitors / ARBs in Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32331829|t=ä. Smoking and coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32362357|t=ä. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum |pdf=|usr=}}
| |
| − | {{tp|p=32314010|t=ä. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs |pdf=|usr=}}
| |
| − | {{tp|p=32346493|t=ä. Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| + | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| | | | |
| | | | |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32146694|t=ä. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China |pdf=|usr=}}
| |
| − | {{ttp|p=32048163|t=2020. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury |pdf=|usr=}}
| |
| − | *'''[[Registries]]'''
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Trials]]'''
| |
| − | *'''[[Candidate Compounds Covid19]]'''
| |
| − | {{tp|p=32239125|t=2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32256547|t=2020. Clinical trials on drug repositioning for COVID-19 treatment |pdf=|usr=}}
| |
| − | {{tp|p=32267301|t=ä. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes |pdf=|usr=}}
| |
| − | {{tp|p=32232552|t=ä. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs |pdf=|usr=}}
| |
| − | {{tp|p=32124179|t=ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| + | *'''[[Case series]]''' |
| | | | |
| | | | |
| − | *'''[[Other routes of infection]]''' | + | *'''[[Registries]]''' |
| − | {{tp|p=32291098|t=ä. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Biophysics of aerosols]]'''
| |
| | | | |
| − | *'''[[Passive protective equipment]]''' | + | *'''[[Trials]]''' |
| | | | |
| | + | *'''[[Candidate Compounds Covid19]]''' |
| | | | |
| − | *'''[[Running your hospital]]'''
| |
| − | {{tp|p=32372843|t=ä. Telecardiolog�a en tiempos de la pandemia COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32338017|t=2020. COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32316737|t=2020. Resumption of activity in gastroenterology departments Recommendations by SEPD, AEEH, GETECCU and AEG |pdf=|usr=}}
| |
| − | {{tp|p=32202911|t=2020. Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18) |pdf=|usr=}}
| |
| − | {{tp|p=32329046|t=2020. Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) para el manejo de pacientes con esclerosis multiple durante la pandemia de SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32329045|t=2020. Herramientas de salud digital para superar la brecha de atencion en epilepsia antes, durante y despues de la pandemia de COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303331|t=2020. Covid-19, the pandemic war: Implication for neurologists |pdf=|usr=}}
| |
| − | {{tp|p=32354651|t=ä. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network |pdf=|usr=}}
| |
| − | {{tp|p=32320999|t=2020. CHALLENGES IN THE FIGHT AGAINST THE COVID-19 PANDEMIC IN UNIVERSITY HOSPITALS |pdf=|usr=}}
| |
| − | {{ttp|p=C7102575|t=ä. Preventing intra-hospital infection and transmission of COVID-19 in healthcare workers |pdf=|usr=}}
| |
| − | {{tp|p=32292260|t=2020. Guidelines for dental care provision during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32341229|t=2020. Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32343342|t=ä. The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders |pdf=|usr=}}
| |
| − | {{tp|p=32345478|t=ä. Is schizophrenia research relevant during the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32349886|t=ä. Long-acting injectable antipsychotics treatment during COVID-19 pandemic ? A new challenge |pdf=|usr=}}
| |
| − | {{tp|p=32299718|t=ä. Ecosystem approaches to the risk for schizophrenia |pdf=|usr=}}
| |
| − | {{tp|p=32327314|t=ä. COVID-19, mobile health and serious mental illness |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| − | *'''[[Mental aspects of health professionals]]''' | + | *'''[[Biophysics of aerosols]]''' |
| | | | |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Passive protective equipment]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Running your hospital]]''' |
| | | | |
| | | | |
| | + | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 218: |
Zeile 138: |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32242087|t=ä. What the stock market tells us about the post-COVID-19 world |pdf=|usr=}}
| |
| − | {{tp|p=32313382|t=ä. Can Global Pharmaceutical Supply Chains Scale Up Sustainably for the COVID-19 Crisis?|pdf=|usr=}}
| |
| − | {{tp|p=32313383|t=2020. A brave new world: Lessons from the COVID-19 pandemic for transitioning to sustainable supply and production |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Educational aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32313309|t=ä. Education and the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32302818|t=2020. Impact Of Sars-Cov-2 And Its Reverberation In Global Higher Education And Mental Health |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Educational aspects of the status hygienicus]]''' |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32300261|t=2020. Severe air pollution events not avoided by reduced anthropogenic activities during COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32333993|t=ä. Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32267109|t=2020. Coronavirus et COVID-19 : le point sur une pandemie galopante |pdf=|usr=}}
| |
| − | {{tp|p=32294667|t=ä. Translating transmissibility measures into recommendations for coronavirus prevention |pdf=|usr=}}
| |
| − | {{tp|p=32236385|t=ä. Outbreak investigation in cargo ship in times of COVID-19 crisis, Port of Santos, Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32320998|t=ä. COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases |pdf=|usr=}}
| |
| − | {{tp|p=32215461|t=ä. The value of mitigating epidemic peaks of COVID-19 for more effective public health responses |pdf=|usr=}}
| |
| − | {{ttp|p=32296266|t=ä. Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32373394|t=ä. Using the contact network model and Metropolis-Hastings sampling to reconstruct the COVID-19 spread on the ?Diamond Princess? |pdf=|usr=}}
| |
| − | {{tp|p=32292631|t=ä. The inflection point about COVID-19 may have passed |pdf=|usr=}}
| |
| − | {{tp|p=32288968|t=2020. A data driven time-dependent transmission rate for tracking an epidemic: a case study of 2019-nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32296594|t=ä. A systematic approach is needed to contain COVID-19 globally |pdf=|usr=}}
| |
| − | {{tp|p=32210236|t=2020. Epidemiological data from the COVID-19 outbreak, real-time case information |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32308203|t=2020. Patients with respiratory symptoms are at greater risk of COVID-19 transmission |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Failure of executive measures]]''' | + | *'''[[Remission, recurrence and persistence]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − |
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32203324|t=ä. COVID-19 and the crisis of national development |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 273: |
Zeile 170: |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32088858|t=ä. Puzzle of highly pathogenic human coronaviruses (2019-nCoV) |pdf=|usr=}}
| + | *'''[[misc.]]''' |
| | | | |
| | | | |
| − | *'''[[misc.]]'''
| |
| − | {{tp|p=32361911|t=ä. Single-cell transcriptome analysis of the novel coronavirus (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive azoospermia (NOA) human male testes |pdf=|usr=}}
| |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | | | |
| | | | |
| | | | |
| − | *'''[[PrePrint scene''']] | + | |
| − | *[https://prelights.biologists.com/ prelights]
| + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| + | |
| − | *[biomol.com assays cytokines general spectrum]
| + | |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| + | |
| − | *[codexdna.com dna synthesis]
| + | |
| − | *[eclipsebio.com around rna]
| + | |
| − | *[btbemulsions.com freud adjuvant kit]
| + | |
| − | *[biophysics.com div.]
| + | |
| − | *[molecular-machines.com microdissection]
| + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
